Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deak

Showing results (851-860 of 878) with videos related to

Pageof 88
Sort By:
Communications Biology|January 20, 2026
Population genomics reveals an ancient origin of heartworms in canidsRosemonde I Power, Swaid Abdullah, Heather S Walden, et al.
Cancer Cell|April 28, 2023
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasisMiles Piper, Maureen Hoen, Laurel B Darragh, et al.
Human Molecular Genetics|May 5, 2018
Functional variants in TBX2 are associated with a syndromic cardiovascular and skeletal developmental disorderNing Liu, Kelly Schoch, Xi Luo, et al.
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Nature|September 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8<sup>+</sup> T cellsLaura Codarri Deak, Valeria Nicolini, Masao Hashimoto, et al.
Nature Communications|May 20, 2022
Automated next-generation profiling of genomic alterations in human cancersLaurel A Keefer, James R White, Derrick E Wood, et al.
Nature Genetics|November 21, 2023
Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implicationsDaniel F Levey, Marco Galimberti, Joseph D Deak, et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews|September 20, 2021
A review of the toxicology of oil in vertebrates: what we have learned following the <i>Deepwater Horizon</i> oil spillRyan Takeshita, Steven J Bursian, Kathleen M Colegrove, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Pageof 88

Showing results (851-860 of 878) with videos related to

Sort By:
Pageof 88
Communications Biology|January 20, 2026
Population genomics reveals an ancient origin of heartworms in canidsRosemonde I Power, Swaid Abdullah, Heather S Walden, et al.
Cancer Cell|April 28, 2023
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasisMiles Piper, Maureen Hoen, Laurel B Darragh, et al.
Human Molecular Genetics|May 5, 2018
Functional variants in TBX2 are associated with a syndromic cardiovascular and skeletal developmental disorderNing Liu, Kelly Schoch, Xi Luo, et al.
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusLucjan Wyrwicz, Arunee Dechaphunkul, Jong-Seok Lee, et al.
Nature|September 28, 2022
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8<sup>+</sup> T cellsLaura Codarri Deak, Valeria Nicolini, Masao Hashimoto, et al.
Nature Communications|May 20, 2022
Automated next-generation profiling of genomic alterations in human cancersLaurel A Keefer, James R White, Derrick E Wood, et al.
Nature Genetics|November 21, 2023
Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implicationsDaniel F Levey, Marco Galimberti, Joseph D Deak, et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews|September 20, 2021
A review of the toxicology of oil in vertebrates: what we have learned following the <i>Deepwater Horizon</i> oil spillRyan Takeshita, Steven J Bursian, Kathleen M Colegrove, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2026
A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanomaElena Garralda, Christoph Markert, Victor Moreno, et al.
Pageof 88